Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N C Fox

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Neurology|September 23, 2009
Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer diseaseW J P Henneman, H Vrenken, J Barnes, et al.
Neurology|July 10, 2009
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET studyA Okello, J Koivunen, P Edison, et al.
Archives of Neurology|June 19, 2001
Autopsy-confirmed familial early-onset Alzheimer disease caused by the l153V presenilin 1 mutationJ C Janssen, P L Lantos, N C Fox, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 16, 2015
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromesN K Magdalinou, R W Paterson, J M Schott, et al.
European Journal of Neurology|August 21, 2012
EFNS task force: the use of neuroimaging in the diagnosis of dementiaM Filippi, F Agosta, F Barkhof, et al.
Translational Psychiatry|November 16, 2016
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathologyR W Paterson, W E Heywood, A J Heslegrave, et al.
AJNR. American Journal of Neuroradiology|May 15, 2007
Magnetization transfer ratio in Alzheimer disease: comparison with volumetric measurementsB H Ridha, M R Symms, D J Tozer, et al.
Neurology|November 20, 2009
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseS Salloway, R Sperling, S Gilman, et al.
Experimental Neurology|December 17, 2009
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levelsA Petzold, M D Chapman, S Schraen, et al.
Neurology|November 4, 2009
The heritability and genetics of frontotemporal lobar degenerationJ D Rohrer, R Guerreiro, J Vandrovcova, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Neurology|September 23, 2009
Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer diseaseW J P Henneman, H Vrenken, J Barnes, et al.
Neurology|July 10, 2009
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET studyA Okello, J Koivunen, P Edison, et al.
Archives of Neurology|June 19, 2001
Autopsy-confirmed familial early-onset Alzheimer disease caused by the l153V presenilin 1 mutationJ C Janssen, P L Lantos, N C Fox, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 16, 2015
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromesN K Magdalinou, R W Paterson, J M Schott, et al.
European Journal of Neurology|August 21, 2012
EFNS task force: the use of neuroimaging in the diagnosis of dementiaM Filippi, F Agosta, F Barkhof, et al.
Translational Psychiatry|November 16, 2016
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathologyR W Paterson, W E Heywood, A J Heslegrave, et al.
AJNR. American Journal of Neuroradiology|May 15, 2007
Magnetization transfer ratio in Alzheimer disease: comparison with volumetric measurementsB H Ridha, M R Symms, D J Tozer, et al.
Neurology|November 20, 2009
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseS Salloway, R Sperling, S Gilman, et al.
Experimental Neurology|December 17, 2009
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levelsA Petzold, M D Chapman, S Schraen, et al.
Neurology|November 4, 2009
The heritability and genetics of frontotemporal lobar degenerationJ D Rohrer, R Guerreiro, J Vandrovcova, et al.
Pageof 12